All companies
Visit website
IMETABOLIC BIOPHARMA
OperatingiMetabolic Biopharma Corporation
Healthcare · Biotech · Founded 2017
Bringing hope to communities through tech-powered biopharma
Valuation cap ⓘ
$25.0M
As of Dec 2023 · from iMetabolic BioPharma Convertible Note 1 · a SAFE/note conversion ceiling, not a priced valuation
Total raised
$342,505
Across 1 round since 2022
Financials
FY2020–FY2025 · from SEC filings · hover any figure for its source$0
−$22K
2020
$0
−$64K
2021
$0
−$83K
2022
$77K
−$201K
2023
$130K
−$120K
2024
$137K
−$100K
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Income statement
Revenue
$0
$0
$0
$76,803
$129,520
$137,329
Cost of goods sold
$0
$0
$0
$0
$0
$0
Gross margin
—
—
—
100%
100%
100%
Net income
-$22,130
-$63,745
-$83,255
-$200,806
-$120,292
-$99,746
Taxes paid
$0
$0
$0
$476
$0
$0
Balance sheet
Cash
$119,176
$62,248
$4,601
$100,587
$82,459
$25,726
Accounts receivable
$0
$0
$0
$76,803
$0
$2
Total assets
$119,176
$64,248
$4,601
$100,587
$82,459
$27,787
Short-term debt
$3,139
$0
$0
$8,949
$47,853
$65,378
Long-term debt
$148,000
$155,471
$172,665
$455,843
$0
$557,779
Total liabilities
$151,139
$155,471
$172,665
$464,792
$47,853
$623,157
Other
Headcount
—
4
4
4
—
4
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$25.0M
Valuation cap
iMetabolic BioPharma Convertible Note 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $342.5K / $1.2MInvestors 275Valuation cap $25M
Reg CF annual-report compliance
Not requiredFewer than 300 holders of record
Filed 3 of 4 annual reports (FY2022–FY2025)
275 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001957114
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.